Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 15;23(10):5518.
doi: 10.3390/ijms23105518.

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

Ya-Chu Tsai  1 , Tsen-Fang Tsai  2
Affiliations
Review

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

Ya-Chu Tsai et al. Int J Mol Sci. .

Abstract

Psoriasis (PSO) and atopic dermatitis (AD) were once considered to be mutually exclusive diseases, but gradually regarded as a spectrum of disease. Shared genetic loci of both diseases were noted in some populations, including Chinese. Shared immunopathogenesis involving Th17, Th1, Th22 cells, or even IL-13 was found in certain stages or phenotypes. This review discusses the overlapping genetic susceptibility, shared cytokines, immune-mediated comorbidities, and clinical presentations. Overlapping conditions could be classified into mainly PSO lesions with AD features or vice versa, concomitant PSO and AD, or disease transformation as a result of biologics treatment.

Keywords: atopic dermatitis; concomitant; overlap; paradoxical; psoriasis; psoriasis dermatitis.

PubMed Disclaimer

Conflict of interest statement

Tsen-fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, GSK-Stiefel, Janssen-Cilag, Leo-Pharma, Merck, Novartis, Pfizer Inc., and UCB Pharma. Ya-chu Tsai has delivered speeches held by AbbVie, Eli Lilly, Janssen-Cilag, Leo-Pharma, Novartis, and Pfizer.

Figures

Figure 1
Figure 1
Psoriasis with overlapping features of eczema.
Figure 2
Figure 2
Immunopathogenesis of atopic dermatitis, psoriasis, and the overlap.
Figure 3
Figure 3
Histopathologic change in between atopic dermatitis and psoriasis.
Figure 4
Figure 4
Subtypes of overlapping psoriasis (PSO) and atopic dermatitis (AD). The phenotypes could be classified into concomitant PSO and AD, mainly PSO lesions with AD features or vice versa, or disease transformation as a result of biologics treatment.
See this image and copyright information in PMC

References

    1. Schäbitz A., Eyerich K., Garzorz-Stark N. So close, and yet so far away: The dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis. J. Intern. Med. 2021;290:27–39. doi: 10.1111/joim.13235. - DOI - PubMed
    1. Griffiths C.E., Armstrong A.W., Gudjonsson J.E., Barker J.N. Psoriasis. Lancet. 2021;397:1301–1315. doi: 10.1016/S0140-6736(20)32549-6. - DOI - PubMed
    1. Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J. Mol. Sci. 2019;20:1475. doi: 10.3390/ijms20061475. - DOI - PMC - PubMed
    1. Ständer S. Atopic Dermatitis. N. Engl. J. Med. 2021;384:1136–1143. doi: 10.1056/NEJMra2023911. - DOI - PubMed
    1. Langan S.M., Irvine A.D., Weidinger S. Atopic dermatitis. Lancet. 2020;396:345–360. doi: 10.1016/S0140-6736(20)31286-1. - DOI - PubMed

Substances